FibroGen, Inc. – NASDAQ:FGEN
FibroGen stock price today
$10.9
+10.32
+1779.31%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
FibroGen stock price monthly change
-44.23%
month
FibroGen stock price quarterly change
-44.23%
quarter
FibroGen stock price yearly change
-28.32%
year
FibroGen key metrics
Market Cap | 42.05M |
Enterprise value | 1.67B |
P/E | -5.68 |
EV/Sales | 11.89 |
EV/EBITDA | -5.96 |
Price/Sales | 12.36 |
Price/Book | -81.15 |
PEG ratio | 6.08 |
EPS | -2.44 |
Revenue | 167.49M |
EBITDA | -214.53M |
Income | -240.46M |
Revenue Q/Q | 54.59% |
Revenue Y/Y | 44.30% |
Profit margin | -208.66% |
Oper. margin | -213.9% |
Gross margin | 85.59% |
EBIT margin | -213.9% |
EBITDA margin | -128.09% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeFibroGen stock price history
FibroGen stock forecast
FibroGen financial statements
| Jun 2023 | 44.31M | -87.68M | -197.84% |
|---|---|---|---|
| Sep 2023 | 40.13M | -63.61M | -158.51% |
| Dec 2023 | 27.13M | -56.23M | -207.21% |
| Mar 2024 | 55.90M | -32.93M | -58.91% |
| Sep 2025 | 49.14M | 22.70M | 46.19% |
|---|---|---|---|
| Oct 2025 | 36.51M | 4.94M | 13.55% |
| Dec 2025 | 37.02M | 5.93M | 16.04% |
| Mar 2026 | 50.01M | 26.08M | 52.15% |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | |
| 2023 | 2.61% |
| Jun 2023 | 515127000 | 575.43M | 111.71% |
|---|---|---|---|
| Sep 2023 | 460426000 | 575.62M | 125.02% |
| Dec 2023 | 423529000 | 585.72M | 138.3% |
| Mar 2024 | 365868000 | 552.02M | 150.88% |
| Jun 2023 | -110.57M | -14.28M | 91.53M |
|---|---|---|---|
| Sep 2023 | -84.53M | 54.21M | -22K |
| Dec 2023 | -18.32M | 10.24M | -246K |
| Mar 2024 | -59.28M | 51.27M | -165K |
FibroGen alternative data
| Aug 2023 | 592 |
|---|---|
| Sep 2023 | 592 |
| Oct 2023 | 592 |
| Nov 2023 | 592 |
| Dec 2023 | 592 |
| Jan 2024 | 592 |
| Feb 2024 | 592 |
| Mar 2024 | 486 |
| Apr 2024 | 486 |
| May 2024 | 486 |
| Jun 2024 | 486 |
| Jul 2024 | 486 |
FibroGen other data
72.22%
+0.79%
of FGEN is owned by hedge funds
147
-13
67.02M
+732.14K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jul 2023 | 0 | 3880 |
| Aug 2023 | 0 | 2000 |
| Sep 2023 | 0 | 2000 |
| Mar 2024 | 50000 | 0 |
| Jun 2024 | 22123 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ADIB DEYAA officer: Chief Medical Officer | Common Stock | 22,123 | $1.17 | $25,884 | ||
Purchase | WETTIG THANE officer: CEO | Common Stock | 50,000 | $1.91 | $95,450 | ||
Sale | HENDERSON JEFFREY WILLIAM director | Common Stock | 2,000 | $1.03 | $2,060 | ||
Sale | HENDERSON JEFFREY WILLIAM director | Common Stock | 2,000 | $1.91 | $3,820 | ||
Sale | HENDERSON JEFFREY WILLIAM director | Common Stock | 2,000 | $2.69 | $5,380 | ||
Sale | CONTERNO ENRIQUE A director, officer.. | Common Stock | 1,880 | $2.8 | $5,264 | ||
Sale | CONTERNO ENRIQUE A director, officer.. | Common Stock | 1,880 | $2.8 | $5,264 | ||
Sale | WETTIG THANE officer: Chief Co.. | Common Stock | 791 | $16.53 | $13,075 | ||
Sale | CHUNG CHRISTINE officer: SVP, China Operations | Common Stock | 5,250 | $16.66 | $87,465 | ||
Sale | CHUNG CHRISTINE officer: SVP, China Operations | Common Stock | 1,000 | $17.46 | $17,460 |
| Patent |
|---|
Application Filling date: 27 Jan 2022 Issue date: 19 May 2022 |
Application Filling date: 19 Jan 2022 Issue date: 12 May 2022 |
Application Filling date: 10 Mar 2021 Issue date: 24 Feb 2022 |
Application Filling date: 21 May 2020 Issue date: 26 Nov 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 6 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 26 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 6 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
FibroGen's Unsteady Course: Assessing Fallout From IPF Failure And The Road Ahead
FibroGen: Despite Some Progress, Roxadustat's Data Disaster Still Haunts It
Pliant Therapeutics' Bexotegrast Shows Promise For Idiopathic Pulmonary Fibrosis
Travere Therapeutics: Upcoming 'PDUFA' Date For Kidney Disease Therapy Is Critical
FibroGen - Biotech
Week In Review: Qiming Launches $500 Million Fund For Listed Healthcare Companies
FibroGen's Cardiovascular Data Mess
-
What's the price of FibroGen stock today?
One share of FibroGen stock can currently be purchased for approximately $10.9.
-
When is FibroGen's next earnings date?
Unfortunately, FibroGen's (FGEN) next earnings date is currently unknown.
-
Does FibroGen pay dividends?
No, FibroGen does not pay dividends.
-
How much money does FibroGen make?
FibroGen has a market capitalization of 42.05M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4.99% to 147.75M US dollars.
-
What is FibroGen's stock symbol?
FibroGen, Inc. is traded on the NASDAQ under the ticker symbol "FGEN".
-
What is FibroGen's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of FibroGen?
Shares of FibroGen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are FibroGen's key executives?
FibroGen's management team includes the following people:
- Mr. Enrique A. Conterno Chief Executive Officer & Director(age: 58, pay: $1,640,000)
- Dr. Elias Kouchakji Senior Vice President of Clinical Devel., Drug Safety & Pharmacovigilance(age: 69, pay: $893,280)
- Mr. Pat Cotroneo Executive Advisor to Chief Executive Officer(age: 61, pay: $797,900)
- Mr. Thane Wettig Chief Commercial Officer(age: 60, pay: $583,030)
- Dr. Mark Eisner M.D., M.P.H. Chief Medical Officer(age: 59, pay: $554,290)
- Mr. James A. Schoeneck Chairman(age: 67, pay: $415,260)
-
How many employees does FibroGen have?
As Jul 2024, FibroGen employs 486 workers.
-
When FibroGen went public?
FibroGen, Inc. is publicly traded company for more then 10 years since IPO on 14 Nov 2014.
-
What is FibroGen's official website?
The official website for FibroGen is fibrogen.com.
-
Where are FibroGen's headquarters?
FibroGen is headquartered at 409 Illinois Street, San Francisco, CA.
-
How can i contact FibroGen?
FibroGen's mailing address is 409 Illinois Street, San Francisco, CA and company can be reached via phone at +41 59781200.
FibroGen company profile:
FibroGen, Inc.
fibrogen.comExchange:
NASDAQ
Full time employees:
486
Industry:
Biotechnology
Sector:
Healthcare
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
409 Illinois Street
San Francisco, CA 94158
San Francisco, CA 94158
CIK: 0000921299
ISIN: US31572Q8087
CUSIP: 31572Q808
